Shares of TESARO $TSRO soared on Monday amid heavy trading volume in response to the news that its Phase 3 Clinical Trial, ENGOT-OV16/NOVA, evaluating PARP inhibitor niraparib in ovarian cancer (OC) patinets , showed good results. The data was showed at the European Society for Medical Oncology 2016 Annual Meeting in Copenhagen.